Collaborative and Other Arrangements - CRISPR Therapeutics AG (Details)	3 Months Ended	12 Months Ended
	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) target	Jul. 01, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payment		$ 125,800,000	$ 84,600,000	$ 63,300,000
Collaborative arrangement research and development expenses		1,100,000,000	184,600,000	318,300,000
CRISPR Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, option payment				$ 30,000,000
Right to license, number of targets (up to) | target				3
Collaborative arrangement development and regulatory potential milestone payments maximum				$ 410,000,000
CRSIPR A&R JDCA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum	$ 200,000,000
Up-front payment	$ 900,000,000
Allocation of net profits and net losses, percent					60.00%
CRSIPR A&R JDCA | CRISPR
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Allocation of net profits and net losses, percent					40.00%
CRISPR DMD/DM1
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum		787,500,000
Up-front payment				175,000,000
Collaborative arrangement, milestone payment		12,500,000	25,000,000
CRISPR Therapeutics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement research and development expenses		230,400,000	101,200,000	60,300,000
CRISPR Therapeutics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Research and development expenses
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement research and development expenses		$ 129,000,000.0	$ 50,600,000	$ 30,100,000